Genetic Studies of Actinic Keratosis Development: Where Are We Now?

被引:2
|
作者
Lee, Young Bok [1 ,2 ,3 ]
Kim, Jong-Il [3 ,4 ,5 ,6 ,7 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Biomed & Hlth Sci, Seoul, South Korea
[2] Catholic Univ Korea, Coll Med, Dept Dermatol, Seoul, South Korea
[3] Seoul Natl Univ, Genom Med Inst GMI, Med Res Ctr, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea
[5] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea
[7] Seoul Natl Univ, Coll Med, Dept Biomed Sci, 103 Daehak Ro, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Actinic keratosis; Cutaneous squamous cell carcinoma; SQUAMOUS-CELL CARCINOMA; CHROMOSOMAL-ABERRATIONS; SKIN; MUTATIONS; CANCER; P53; P16(INK4A); EXPRESSION; PATTERNS; RISK;
D O I
10.5021/ad.23.072
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Actinic keratosis (AK) is a common precancerous skin lesion that can develop into cutaneous squamous cell carcinoma (CSCC). AK is characterized by atypical keratinocytes in the skin's outer layer and is commonly found in sun-exposed areas. Like many precancerous lesions, the development of AK is closely associated with genetic mutations. The molecular biology and transcriptional mechanisms underlying AK development are not well understood. Ultraviolet (UV) light exposure, especially UVA and UVB radiation, is a significant risk factor for AK, causing DNA damage and mutagenic effects. Besides UV exposure, comorbidities like diabetes, rheumatoid arthritis, and psoriasis may also influence AK development. AK patients have shown associations with various internal malignancies, indicating potential vulnerability in cancer-associated genes. Treatment for AK includes cryosurgery, electrodesiccation and curettage, chemotherapeutic creams, photodynamic therapy, or topical immune-modulators. Genomic studies have identified genetic aberrations in AK, with common mutations found in genes like TP53, NOTCH1, and NOTCH2. The progression from AK to CSCC involves chromosomal aberrations and alterations in oncogenes and tumor-suppressor genes. The functional relationships among these genes are not fully understood, but network analysis provides insights into their potential mechanisms. Further research is needed to enhance our understanding of AK's pathogenesis and develop novel therapeutic approaches.
引用
收藏
页码:389 / 399
页数:11
相关论文
共 50 条
  • [21] Pim kinases in hematological malignancies: where are we now and where are we going?
    Mondello, Patrizia
    Cuzzocrea, Salvatore
    Mian, Michael
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [22] Immunotherapy for head and neck cancer: where are we now and where are we going?
    Bauml, Joshua M.
    Aggarwal, Charu
    Cohen, Roger B.
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [23] Early detection of pancreatic cancer: Where are we now and where are we going?
    Zhou, Bin
    Xu, Jian-Wei
    Cheng, Yu-Gang
    Gao, Jing-Yue
    Hu, San-Yuan
    Wang, Lei
    Zhan, Han-Xiang
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (02) : 231 - 241
  • [24] Geriatric Drug Evaluation Where Are We Now and Where Should We Be in the Future?
    Cho, Seongeun
    Lau, S. W. Johnny
    Tandon, Veneeta
    Kumi, Kofi
    Pfuma, Elimika
    Abernethy, Darrell R.
    ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (10) : 937 - 940
  • [25] Immunotherapy for esophageal cancer: Where are we now and where can we go
    Shoji, Yoshiaki
    Koyanagi, Kazuo
    Kanamori, Kohei
    Tajima, Kohei
    Ogimi, Mika
    Ninomiya, Yamato
    Yamamoto, Miho
    Kazuno, Akihito
    Nabeshima, Kazuhito
    Nishi, Takayuki
    Mori, Masaki
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (19) : 2496 - 2501
  • [26] Stroke Mimics at 30 Years: Where We Have Been, Where We Are Now, and Where We Are Going
    Khawar, Haroon
    Mcfarlane, Spencer
    Libman, Richard B.
    STROKE, 2025, 56 (04) : 1061 - 1068
  • [27] Phosphodiesterase 7 as a therapeutic target-Where are we now?
    Zorn, Alina
    Baillie, George
    CELLULAR SIGNALLING, 2023, 108
  • [28] Malignant transformation of oral lichen planus: where are we now?
    Gonzalez-Moles, Miguel angel
    Ramos-Garcia, Pablo
    MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2025, 30 (01): : e65 - e75
  • [29] Prevention of posttraumatic osteoarthritis at the time of injury: Where are we now, and where are we going?
    Mason, Deborah
    Englund, Martin
    Watt, Fiona E.
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2021, 39 (06) : 1152 - 1163
  • [30] COVID-19 vaccine: where are we now and where should we go?
    Soleimanpour, Saman
    Yaghoubi, Atieh
    EXPERT REVIEW OF VACCINES, 2021, 20 (01) : 23 - 44